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A B S T R A C T
Purpose
The Dutch MRI Screening Study on early detection of hereditary breast cancer started in 1999. We
evaluated the long-term results including separate analyses of BRCA1 and BRCA2 mutation
carriers and first results on survival.
Patients and Methods
Women with higher than 15% cumulative lifetime risk (CLTR) of breast cancer were screened with
biannual clinical breast examination and annual mammography and magnetic resonance imaging
(MRI). Participants were divided into subgroups: carriers of a gene mutation (50% to 85% CLTR)
and two familial groups with high (30% to 50% CLTR) or moderate risk (15% to 30% CLTR).
Results
Our update contains 2,157 eligible women including 599 mutation carriers (median follow-up of 4.9
years from entry) with 97 primary breast cancers detected (median follow-up of 5.0 years from
diagnosis). MRI sensitivity was superior to that of mammography for invasive cancer (77.4% v
35.5%; P  .00005), but not for ductal carcinoma in situ. Results in the BRCA1 group were worse
compared to the BRCA2, the high-, and the moderate-risk groups, respectively, for mammography
sensitivity (25.0% v 61.5%, 45.5%, 46.7%), tumor size at diagnosis  1 cm (21.4% v 61.5%,
40.9%, 63.6%), proportion of DCIS (6.5% v 18.8%, 14.8%, 31.3%) and interval cancers (32.3% v
6.3%, 3.7%, 6.3%), and age at diagnosis younger than 30 years (9.7% v 0%). Cumulative distant
metastasis-free and overall survival at 6 years in all 42 BRCA1/2 mutation carriers with invasive
breast cancer were 83.9% (95% CI, 64.1% to 93.3%) and 92.7% (95% CI, 79.0% to 97.6%),
respectively, and 100% in the familial groups (n  43).
Conclusion
Screening results were somewhat worse in BRCA1 mutation carriers, but 6-year survival was high
in all risk groups.
J Clin Oncol 28:5265-5273. © 2010 by American Society of Clinical Oncology
INTRODUCTION
Women with a genetic predisposition for breast
cancer face a cumulative lifetime risk (CLTR) of
breast cancer varying between 15% and 85%.1-4
The risk of breast cancer can be reduced by
prophylactic surgery or chemoprevention.5-9 A
promising strategy to reduce the risk of breast
cancer death is early diagnosis by intensive sur-
veillance. First results of various large prospective
studies have shown that magnetic resonance im-
aging (MRI) appears to be about twice as sensitive
as mammography in detecting tumors in women
with a susceptibility to breast cancer.10-21 Al-
though most guidelines now recommend MRI
screening in BRCA1/2 mutation carriers,22-24 no
consensus on the screening protocol exists for all
risk groups. Only a few (small) studies investi-
gated screening results inBRCA1 andBRCA2mu-
tation carriers separately. Furthermore, data on
mortality are lacking.
Therefore, based on an extensive update and
enlargement of ourMRI Screening Study (MRISC),
the largest (n  2,157) in the world to our knowl-
edge, the objectives of our current study were: eval-
uation of screening effects in four different genetic
risk groups focusing on (potential) differences be-
tween BRCA1 and BRCA2mutation carriers and to
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study, for the first time to our knowledge, effects on observed breast
cancer mortality.
PATIENTS AND METHODS
Study Population
The DutchMRISC study is a nonrandomized prospective cohort study.
Between November 1, 1999, andMarch 1, 2006, 2,275 women with a genetic
risk of breast cancer were enrolled by six cancer and/or university centers
(Appendix Table A1, online only). The study was approved by the ethics
committees of all centers. All women provided written informed consent.
Women (age, 25 to 75 years) with a cumulative lifetime risk (CLTR) of
developing breast cancer of 15% due to a familial or genetic predisposition
were eligible for the study.10,25Womenwith symptomsorapersonalhistoryof
breast cancer were excluded. At study entry, participants were divided into
subgroups according to their estimated CLTR of breast cancer: carriers of
BRCA1, BRCA2, or other mutations (50% to 85% CLTR), a high-risk group
(30%to50%CLTR), andamoderate-risk group (15%to30%CLTR)without
a documented gene mutation. These CLTR categories for breast cancer were
based on themodified tables of Claus.4,25
Study Protocol
Participating women were screened with biannual clinical breast exam-
ination (CBE) and annual (simultaneous) two-viewmammography andMRI
of the breasts. Through the years, all centers changed from conventional to
digital mammography. In all centers, dynamic contrast enhanced MRI was
performed on a 1.5 Tesla system (Siemens, Erlangen, Germany). Breast MRI
workstations were used to perform time-signal intensity curves. During the
study, the MR units were upgraded and scanning protocols improved. The
mammography andMRI were scored in a standardized way according to the
Breast Imaging Reporting and Data System (BI-RADS),26,27 and were inde-
pendently evaluated. We defined as positive a mammography or MRI with
Women
included
(N = 2,275)
Non-Hodgkin’s lymphoma
(n = 1)
Either did not meet the inclusion criteria (including 
   those who ultimately proved to be non-mutation 
   carriers in a BRCA1/2 family) or withdrew from the
   study before the first screening visit
Eligible for analysis:
    BRCA1 mutation carriers
    BRCA2 mutation carriers
    PTEN/TP53 mutation carriers
    High-risk women
    Moderate-risk women
Breast tumors
    Screen-detected cancers 
    Interval cancers
(n = 91; DCIS = 15)
(n = 78; DCIS = 14)
(n = 13; DCIS = 1)
Breast tumors detected at 
   prophylactic mastectomy
For analysis of the screening variables 
and for the comparison of the methods 
of detection
(n = 6; DCIS = 4)
Malignant breast tumors in 93 patients; all followed 
   for relapse and survival
Breast tumors excluded for analysis of the screening variables and for the comparison
    of the methods of detection:
       Cancers in women who refused or did not receive further MRI screening, 
          detected more than 1 year from the last screening MRI
       Cancers detected in women who received only CBE at the screening 
          round concerned, including two pregnant women
       Cancers detected on additional imaging after screening imaging, but at a different
          location from the first lesion
Breast tumors with screening data that 
   included the results of both 
     imaging methods:
        Screen-detected cancers
        Interval cancers
(n = 75; DCIS = 13)
(n = 66; DCIS = 12)
(n = 9; DCIS = 1)
(n = 16)
(n = 8; interval cancers = 3)
(n = 6; interval cancer = 1)
(n = 2)
(n = 97; DCIS = 19)
(n = 2,157)
(n = 422)
(n = 172)
(n = 5)
(n = 1,069)
(n = 489)
(n = 118)
Fig 1. Flow chart describing the number of
women and number of breast tumors avail-
able for statistical analysis. The numbers of
DCIS and interval cancers are included in the
total number of breast tumors. DCIS, ductal
carcinoma in situ; MRI, magnetic resonance
imaging; CBE, clinical breast examination.
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BI-RADS score 3, 0, 4, or 5 and a CBE that was classified as uncertain or
suspicious, because those were the results that triggered an additional exami-
nation. An interval cancer was defined as a carcinoma detected by the woman
between two roundsof screening, after initially negativefindings on screening.
The diagnosis of a malignant tumor was based on the results of histologic
examination. Patientswere subsequently treated according to standard proto-
cols for local and systemic (adjuvant) treatment. For a more detailed descrip-
tion of the screening protocol10,25,28 see the online-only Appendix.
The records of all womenwith breast cancer detected beforeMarch 1,
2006,were inspected for the occurrence of a relapse and/or death (using the
municipal registry) until January 1, 2009 (Figs 1 and Appendix Fig A1,
online only).
Statistical Analysis
Overall breast cancer detection rates were calculated as the total number
of breast cancers detected (including ductal carcinoma in situ [DCIS]) per
1,000woman-years at risk; aPoissondistributionwas assumed to calculate the
95% CIs. Detection rates were compared using exact tests (based on the
binomial distribution).
For each of the three screening modalities, we calculated sensitivity,
specificity, and positive predictive value, including 95% CIs based on the
binomial distribution. The differences between sensitivity of screening
modalities were tested by a McNemar’s test. Sensitivity was compared
between the different subgroups with the use of Fisher’s exact test. For
the analysis of the screening variables and for the comparison of the
methods of detection of breast cancer, we used only the screening data
that included the results of both imaging methods at the screening
rounds (n  75, Fig 1).
Differences in proportion of interval cancers, age at diagnosis (con-
tinuous variable without normal distribution), DCIS or invasive cancer,
tumor size (continuous variable without normal distribution), nodal sta-
tus, histologic type, histologic grade, estrogen receptor, and progesterone
receptor status between subgroups were analyzed by Fisher’s exact, Mann-
Whitney, or Kruskal-Wallis test. A two-sided P value of lower than .05 was
considered statistically significant. The cumulative distant metastasis-free
and overall survival were calculated by using the Kaplan-Meier method.
Statistical analyses were performed using SPSS (SPSS 16.0 for Windows,
SPSS Institute, Chicago, IL) and STATA 11SE (Stata Corp, College Sta-
tion, TX).
RESULTS
Patients
Of the 2,275 women included in the study, 118 did not meet the
various inclusion criteria (Figs 1, A1).10,25 The 2,157 eligible women
included 599 carriers of a pathogenic gene mutation in BRCA1
(n422),BRCA2 (n172), orPTEN/TP53 (n5), 1,069women in
the high-risk and 489 women in the moderate-risk group (Tables 1
and 2). Median follow-up time from entry was 4.9 years (mean, 4.0;
range, 0.1 to 6.3 years), with 8,760woman-years at risk. Themean age
at entrywas 40.1 years (range, 19 to 75 years) for the total study group,
and 38.7, 40.0, 40.8, and 40.0 years for the subgroups ofwomenwith a
BRCA1 mutation, a BRCA2 mutation, the high-risk, and the
moderate-risk group, respectively. In themutation carriers, high- and
moderate-risk group, respectively, 22%, 16%, and 15%had no previ-
ous breast cancer screening before study entry.
Breast Cancers
ToMarch 1, 2006, a total of 98 malignant tumors were detected
in 94women (Fig 1). Of the 97 breast cancers, 78 (80%)were invasive
and19 (20%)wereDCIS (Table 1); 78 breast cancerswere detected by
screening (15 in the first and 63 in subsequent screening rounds) and
six by chance at prophylactic mastectomy. Ten of 13 interval cancers
were found in BRCA1mutation carriers. Nine of 13 interval cancers
weredetectedwithin1year (median,8; range, 3 to10months;Table3)
and fourmore than 1 year since last screening by imaging (Fig 1). The
median tumor size of all invasive interval cancerswas 20mm(n 12;
range, 12 to 50mm).
The overall rate of detection was 10.4 per 1,000 woman-years at
risk (Table 2), with the highest rate in BRCA2mutation carriers (39.2
per 1,000), which was due partly to the high incidence of DCIS in this
subgroup (7.4 per 1,000). No clear differences (P .50) in detection
rates between the high- and moderate-risk groups were observed, as
discussed before.29
Screening Performance
Consideringonly those75breast cancers (including13DCISand
nine interval cancers)with results of both imagingmethods (Table 3),
32 (43%) were detected only by MRI screening (16 of the 32 in
mutation carriers); five of these were also detected by CBE. A total of
19 breast cancers (25%)were detected by bothMRI andmammogra-
phy screening; five also by CBE. Twelve breast cancers (16%) were
detected only by mammography screening (including eight DCIS);
one also by CBE. Three breast cancers were detected only by CBE
screening (4%).Nine (12%)were true interval cancers.Tumor sizesof
Table 1. Total No. of Breast Cancers Detected, Divided Into Screen-Detected Cancers and Interval Cancers, According to Risk Group
Parameter
No. of
Women
No. of Cancers Detected No. of Screen-Detected Cancers No. of Interval Cancers
Total Invasive DCIS Total Invasive DCIS Total Invasive DCIS
Mutation carrier
BRCA1 422 35 (4) 31 (2) 4 (2) 21 19 2 10 10 0
BRCA2 172 18 (2) 13 5 (2) 15 12 3 1 1 0
PTEN/TP53 5 1 0 1 1 0 1 0 0 0
Risk group
High 1,069 27 23 4 26 22 4 1 1 0
Moderate 489 16 11 5 15 11 4 1 0 1
Total 2,157 97 (6) 78 (2) 19 (4) 78 64 14 13 12 1
Abbreviations: DCIS, ductal carcinoma in situ; PM, prophylactic mastectomy.
Indicates No. of cancers detected by PM (in parenthesis). Six breast cancers were detected in a specimen from a PM: four breast cancers (two invasive breast
cancers, two DCIS) in BRCA1 mutation carriers, and two breast cancers (two DCIS) in BRCA2 mutation carriers as indicated in parentheses. These cancers are
included in the total No. of breast cancers detected, but not included in the No. of interval cancers.
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invasive tumors were largest in the group of interval cancers (median
size, 16.5 mm) and smallest in the group of cancers detected by MRI
only (median size, 9 mm; P .002; Table 3). Age at diagnosis tended
to be lower (P .10) in the patient group with interval cancers.
For all 75 breast cancers (invasive plus in situ), the sensitivitywas
20.6% for CBE, 41.3% for mammography, and 70.7% for MRI, re-
spectively (Table 4). The difference in sensitivity between mammog-
raphy and MRI is significant (P  .0016). Including only invasive
cancers increased MRI sensitivity to 77.4% but decreased the mam-
mography sensitivity to 35.5% (n 62; P .00005). In contrast, for
DCIS cancers only, the sensitivity of mammography (69.2%) was
much higher than that of MRI sensitivity (38.5%), but, due to small
numbers,not significant (n13;P .388).Theoverall specificitywas
97.9% for CBE, 94.6% for mammography, and 89.7% forMRI.
Regarding women younger than 40 years of age at diagnosis, in
five of 26 patients, the tumor was only detected by mammography
(three patients with DCIS), while in 11 women the tumor was only
detected by MRI (one patient with DCIS; Appendix Table A2, on-
line only).
Looking more specifically at mutation carriers, the mammogra-
phy sensitivity was significantly lower (P  .04) in BRCA1 (25.0%)
than inBRCA2mutation carriers (61.5%). Strikingly, the sensitivity of
MRIwasmuchhigher than that ofmammography inBRCA1 (n24;
66.7 v 25.0%; P  .0129) and only slightly higher (n  13; 69.2 v
Table 2. Detection of Breast Cancers (including ductal carcinoma in situ), Including Screen-Detected Cancers (n  78) and Interval Cancers (n  13),
According to Risk Group
Parameter
No. of
Women
Woman-Years
at Risk
No. of
Screen-Detected
and Interval
Cancers
Rate of Detection†
All Cancers Invasive Cancers
Total Invasive Detection Rate 95% CI Detection Rate 95% CI
Mutation carrier
BRCA1 422 1,178 31 29 26.3 17.9 to 37.3 24.6 16.5 to 35.3
BRCA2 172 408 16 13 39.2 22.4 to 63.7 31.9 17.0 to 54.5
PTEN/TP53 5 13 1 0 — — — —
Risk group
High 1,069 4,838 27 23 5.6‡ 3.7 to 8.1 4.8‡ 3.0 to 7.1
Moderate 489 2,324 16 11 6.9 3.9 to 11.2 4.7 2.4 to 8.5
Total 2,157 8,760 91 76 10.4 8.4 to 12.8 8.7 6.8 to 10.9
The number of cancers and rates of detection are excluding the six cancers detected by chance at prophylactic mastectomy. Overall rates of detection (invasive
plus in situ), when including the breast cancers detected at prophylactic mastectomy (in total 97 breast cancers, see Table 1), are 11.1, 29.7, and 44.1 per 1,000
woman-years at risk for the total study group, BRCA1 mutation carriers, and BRCA2 mutation carriers, respectively. Rates of detection of invasive cancers, including
breast cancers detected at prophylactic mastectomy, are 8.9 and 26.3 per 1,000 woman-years at risk for the total study group and BRCA1 mutation carriers,
respectively.
†Rates shown are per 1,000 woman-years at risk.
‡Differences in rates of detection between the high- and moderate-risk group for all cancers (P  .50) and invasive cancers (P  1.0) are not significant.
Table 3. Comparison of the Methods of Detection of Breast Cancer (using only the screening data that included the results of both imaging methods at the
screening rounds, n  75)
Parameter
MRI Screening 
Mmg Screening 
CBE Screening  or –
MRI Screening 
Mmg Screening 
CBE Screening  or –
MRI Screening –
Mmg Screening 
CBE Screening  or –
MRI Screening 
Mmg Screening –
CBE Screening 
Interval
Cancers
Total No.
of Breast
Cancers
Mutation carrier
BRCA1 11 4 2 (2) 1 6 24 (2)
BRCA2 4 (1) 5 (1) 3 (1) 0 1 13 (3)
PTEN 1 (1) 0 0 0 0 1 (1)
Risk group
High 9 (1) 8 2 (1) 2 1 22 (2)
Moderate 7 2 5 (4) 0 1 (1) 15 (5)
Total 32 (3) 19 (1) 12 (8) 3 9 (1) 75 (13)
Median tumor size of invasive
tumors, mm 9 15 13.5 10.0 16.5 12.0
Range 4-45 4-35 4-20 5-10 12-45 4-45
Invasive tumors  1 cm, % 62.1 33.3 25.0 100.0 0 45.2
Median age at diagnosis, years 45.5 49.1 41.5 45.7 38.1 45.2
Range 36-53 27-68 31-61 32-49 28-53 27-68
NOTE. Numbers in parenthesis indicate ductal carcinoma in situ. The results have been calculated on the basis of data on 75 of the 97 cancers (Fig 1). A
mammographic or MRI study with a Bi-RADS score of 3, 0, 4 or 5 and a clinical breast examination that was classified as uncertain or suspicious was defined as
positive (). A mammographic or MRI study with a Bi-RADS score of 1 or 2 and a clinical breast examination that was classified as not suspicious was defined as
negative ().
Abbreviations: MRI, magnetic resonance imaging; Mmg, mammography; CBE, clinical breast examination; Bi-RADS, Breast Imaging Reporting and Data System.
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61.5%; P 1.0) in BRCA2mutation carriers. The sensitivity of CBE
was highest in the high- andmoderate-risk groups, but overall differ-
ences were not significant (P .22). The specificity of each screening
method did not differ much between the risk groups.
Patient and Tumor Characteristics
The age at diagnosis (mean 44.4; median, 44.6; range, 27 to 68
years) differed overall significantly (P .0006) between the different
risk groups (Table 5): 58.1% of the BRCA1mutation carriers had an
age at diagnosis of breast cancer younger than 40 years (9.7%younger
than 30 years of age), compared with 50.0% in BRCA2 mutation
carriers, 18.5%in thehigh-risk group, andonly6.3%in themoderate-
risk group.
Strikingly, DCIS was found in only 6.5% of the BRCA1-
associated tumors, in contrast to 18.8% of the BRCA2-associated
cases, but differences between risk groups were not significant
(Table 5). In BRCA1 mutation carriers, 35.7% of the invasive
tumors were larger than 2 cm compared to only 7.7% in BRCA2
mutation carriers. Both inBRCA2mutation carriers and inwomen
at high and moderate risk, a large proportion of the invasive
tumors was smaller than 1 cm (61.5%, 40.9%, and 63.6%, respec-
tively). The tumor sizes differed significantly between the four
subgroups (P  .003), and also between BRCA1 and BRCA2 mu-
tation carriers separately (P .0045).
The distribution of nodal status did not differ between the differ-
ent risk groups (P  .42). Grade 1 tumors were mostly found in
womenat highormoderate risk (52.2%and54.5%, respectively). The
women with a BRCA1 mutation had a high proportion of grade 3
tumors (77.8%), in addition to a high percentage of tumors that were
negative for steroid receptors.
Disease-Free and Overall Survival
The median follow-up from time of diagnosis of the primary
tumors in the 89 surviving patients was 5.0 years (range, 1.7 to 8.4
Table 4. Sensitivity, Specificity, and PPV of CBE, Mammography, and MRI (using only the screening data that included the results of both imaging methods
at the screening rounds)†
Parameter
Sensitivity Specificity PPV
% 95% CI No./Total No. % 95% CI No./Total No. % 95% CI No./Total No.
CBE
Any breast cancer 20.6 11.7 to 32.1 14/68 97.9 97.5 to 98.2 5,688/5,810 10.3 5.7 to 16.7 14/136
Invasive breast cancer 21.8 11.8 to 32.1 12/55
DCIS 15.4 1.9 to 45.4 2/13
Mutation carrier (any breast cancer)
BRCA1 13.0‡ 2.8 to 33.6 3/23 96.9 95.7 to 97.9 982/1,013 8.8 1.8 to 23.7 3/34
BRCA2 7.7 0.2 to 36.0 1/13 98.3 96.4 to 99.4 349/355 14.3 0.4 to 57.9 1/7
Risk group (any breast cancer)
High 31.6 12.6 to 56.5 6/19 98.2 97.7 to 98.7 3,030/3,085 9.8 3.7 to 20.2 6/61
Moderate 33.3 9.9 to 65.1 4/12 97.8 96.9 to 98.6 1,317/1,346 12.1 3.4 to 28.2 4/33
Mammography
Any breast cancer 41.3 30.1 to 53.3 31/75 94.6 94.0 to 95.1 5,844/6,178 8.5 5.8 to 11.8 31/365
Invasive breast cancer 35.5 23.7 to 48.7 22/62
DCIS 69.2 38.6 to 90.9 9/13
Mutation carrier (any breast cancer)
BRCA1 25.0‡ 9.8 to 46.7 6/24 94.6 93.0 to 95.9 995/1,052 9.5 3.6 to 19.6 6/63
BRCA2 61.5 32.6 to 86.1 8/13 93.8 90.9 to 96.0 349/372 25.8 11.9 to 44.6 8/31
Risk group (any breast cancer)
High 45.5 24.4 to 67.8 10/22 94.6 93.8 to 95.3 3,129/3,308 5.3 2.6 to 9.5 10/189
Moderate 46.7 21.3 to 73.4 7/15 94.8 93.5 to 95.9 1,360/1,435 8.5 3.5 to 16.8 7/82
MRI
Any breast cancer 70.7 59.0 to 80.6 53/75 89.7 88.9 to 90.4 5,539/6,178 7.7 5.8 to 9.9 53/692
Invasive breast cancer 77.4 65.0 to 87.1 48/62
DCIS 38.5 13.8 to 68.4 5/13
Mutation carrier (any breast cancer)
BRCA1 66.7‡ 44.7 to 84.4 16/24 91.0 89.1 to 92.6 957/1,052 14.4 8.5 to 22.4 16/111
BRCA2 69.2 38.6 to 90.9 9/13 91.9 88.7 to 94.5 342/372 23.1 11.1 to 39.3 9/39
Risk group (any breast cancer)
High 77.3 54.6 to 92.2 17/22 89.1 87.9 to 90.1 2,946/3,308 4.5 2.6 to 7.1 17/379
Moderate 66.7 38.4 to 88.2 10/15 89.5 87.8 to 91.0 1,284/1,435 6.2 3.0 to 11.1 10/161
Abbreviations: PPV, positive predictive value; CBE, clinical breast examination; MRI, magnetic resonance imaging; Bi-RADS, Breast Imaging Reporting and Data
System.
The results have been calculated on the basis of data on 75 of the 97 cancers (Fig 1).
†A mammographic or MRI study with a Bi-RADS score of 3, 0, 4 or 5 and a clinical breast examination that was classified as uncertain or suspicious was defined
as positive. A mammographic or MRI study with a Bi-RADS score of 1 or 2 and a clinical breast examination that was classified as not suspicious was defined as
negative.
‡We compared for all three screening modalities the differences in sensitivity between risk groups overall, and separately between BRCA1 mutation carriers and
any other risk group. For CBE and MRI we found no significant differences, while for mammography we only found a significant difference between BRCA1 and
BRCA2 mutation carriers (P  .04).
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years). Eleven of 93 patients with breast cancer developed a recur-
rence: seven of 11 with a gene mutation (Appendix Table A3, online
only). All but one were screen-detected tumors. Distant metastasis
occurred in five patients (allBRCA1/2mutation carriers), generally at
a young age. The primary tumor sizes were 2, 9, 20, 25, and 40 mm,
and only one tumor was node positive. Four patients died (three of
31 9.7%of allBRCA1 andone of 16 6.3%of allBRCA2mutation
carriers). The cumulative distant-metastasis free and overall survival
at 6 years in the 42 BRCA1/2 mutation carriers with invasive cancer
were 83.9% (95%CI, 64.1% to 93.3%) and 92.7% (95%CI, 79.0% to
97.6%), respectively (Appendix Fig A2, online only). None of the 43
(non-BRCA1/2) patients in the high- and moderate-risk groups (34
with invasive cancer) developed distant metastasis or died (100%
cumulative survival). Four other patients (three with DCIS) devel-
oped only a local recurrence or new ipsilateral tumor and two others
developed a contralateral breast cancer.
DISCUSSION
In our previous study, we compared tumor characteristics of detected
breast cancers with those of age-matched symptomatic controls, con-
cluding that intensive surveillance including MRI can detect breast
cancer at an early stage.10 Our present data showing comparable
results confirm that conclusion. Sensitivity and specificity of MRI
screening showed no major differences between the four subgroups
studied. In contrast, the sensitivity ofmammographywas significantly
higher in BRCA2mutation carriers than in BRCA1mutation carriers
(61.5% v 25.0%; P .04). This can at least partly be explained by the
higher proportion of DCIS in BRCA2 than in BRCA1mutation carri-
ers and the fact that, in our study, mammography had a higher
(P .033) sensitivity in DCIS (69.2%) compared to invasive tumors
(35.5%). Based on a review by two experienced radiologists in the
Table 5. Characteristics of Primary Breast Cancers Detected, Including Screen-Detected Cancers (n  78) and Interval Cancers (n  13), According to
Risk Group†
Characteristic
Risk Group
P
BRCA1 BRCA2 High Moderate Total
Overall Comparison
Between Four Subgroups
Comparison
BRCA1 v BRCA2No. % No. % No. % No. % No. %
No. of breast cancers detected 31 16 27 16 91‡
No. of interval cancers 10 32.3 1 6.3 1 3.7 1 6.3 13 14.3 .01 .07
Age at diagnosis, years
 30 3 9.7 0 0 0 3 3.3
30-39 15 48.4 8 50.0 5 18.5 1 6.3 30‡ 33.0
40-49 9 29.0 6 37.5 10 37.0 10 62.5 35 38.5
50-59 4 12.9 1 6.3 9 33.3 4 25.0 18 19.8
 60 0 1 6.3 3 11.1 1 6.3 5 5.5 .0006 .29
Tumor size
DCIS 2 6.5 3 18.8 4 14.8 5 31.3 15‡ 16.5 .16 .32§
Invasive tumors, cm
 1 6 21.4 8 61.5 9 40.9 7 63.6 30 40.5
1-2 12 42.9 4 30.8 10 45.5 3 27.3 29 39.2
 2 10 35.7 1 7.7 3 13.6 1 9.1 15 20.3 .003 .0045
Nodal status
Negative 18 64.3 8 66.7 14 66.7 10 90.9 50 69.4
Positive 10 35.7 4 33.3 7 33.3 1 9.1 22 30.6 .42 1
Histologic type
Ductal 24 85.7 10 76.9 17 73.9 8 72.7 59 78.7
Lobular 0 1 7.7 3 13.0 2 18.2 6 8.0
Tubular 1 3.6 0 2 8.7 1 9.1 4 5.3
Medullary 3 10.7 2 15.4 0 0 5 6.7
Adenoid cystic 0 0 1 4.3 0 1 1.3 .18 .52
Histologic grade
1 1 3.7 2 18.2 12 52.2 6 54.5 21 29.2
2 5 18.5 3 27.3 10 43.5 5 45.5 23 31.9
3 21 77.8 6 54.5 1 4.3 0 28 38.9 .001 .15
Estrogen receptor status
Positive 5 17.9 7 63.6 19 86.4 10 90.9 41 56.9
Negative 23 82.1 4 36.4 3 13.6 1 9.1 31 43.1 .001 .02
Progesterone receptor status
Positive 5 17.9 7 58.3 18 85.7 10 90.9 40 55.6
Negative 23 82.1 5 41.7 3 14.3 1 9.1 32 44.4 .001 .02
Abbreviation: DCIS, ductal carcinoma in situ.
No. of cancers and characteristics of breast cancers detected are excluding six cancers detected at prophylactic mastectomy.
†Percentages are based on the numbers of women with known data; numbers with missing data are not shown.
‡Including one DCIS in a PTEN mutation carrier.
§P  .68 for the comparison between BRCA2 mutation carriers and the moderate-risk group.
P  .32 for the comparison between BRCA2 mutation carriers and the moderate-risk group.
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context of a quality control side study, a major contributing factor to
false-negativeMRI diagnoses was nonenhancingDCIS, not visible on
theMRIs (even retrospectively).28 The gain of sensitivity ofMRI over
mammography was smaller in BRCA2 mutation carriers (69.2% v
61.5%; P 1.0) than in the other subgroups, including BRCA1mu-
tation carriers (66.7% v 25.0%; P .0129). A similar observation was
made in a subgroup analysis and in a review of all images of all cancer
cases within the MARIBS (Magnetic Resonance Imaging Breast
Screening) study.12,20,30Also in retrospect,only twoof their six casesof
DCIS were visible on MRI in contrast to all on mammography.30
These results are in contrast to thoseofKuhl et al,13,16,31which showed
a highMRI sensitivity for DCIS (as well as for invasive cancer).
Several large prospective MRI screening studies with more than
18 breast cancers detected have been reported.10-21 These studies,
includingourupdate, showsomevariations in results,whichmightbe
caused by numerous differences in study populations andmethods as
recently extensively discussed by Leach20 andKlijn.21 Nevertheless, all
studies concluded that the sensitivity ofMRI (range, 68%to91%)was
approximately twice that of mammography (range, 32% to 40%). In
contrast, with the exception of one study,13 the specificity of MRI
(range, 81% to 97%) was lower than that of mammography (range,
93% to 100%). Combination ofMRI andmammography resulted in
higher sensitivities (range, 80% to 94%).17
In our study, overall 42.7% of the breast cancers were detected
only byMRI screening (median, 9 mm; with 62% of tumors 1 cm,
Table 3): 45.8% of the breast cancers in BRCA1 mutation carriers,
30.8% in BRCA2mutation carriers, 40.9% in high-risk women, and
46.7% in moderate-risk women. These results, in combination with
the detectionof a favorable tumor stage (particularly in themoderate-
risk group), support the recommendation of the American Cancer
Society to use annual MRI screening not only for BRCA1/2mutation
carriers, but for all women with an approximately 20% to 25% or
greaterCLTRofbreast cancerdue to a familial predisposition.22How-
ever, the cost-effectiveness of MRI screening29,32-34 should be evalu-
ated for all risk groups separately.
Interestingly, due to our extensive update we were now able to
demonstrate differences betweenBRCA1 andBRCA2mutation carri-
ers. Apart from lower mammography sensitivity (25.0% v 61.5%;
P  .04), BRCA1 mutation carriers showed a higher proportion of
interval cancers (32% v6%;P .07), anonsignificantly lowerpropor-
tion of DCIS (6.5% v 18.8%) and a significant greater frequency
(P .0045) of unfavorable tumor size ( 2 cm) at diagnosis (35.7% v
7.7%). These relatively poor results inBRCA1mutation carriers could
bepartly explainedbydifferentmammographic features35 andgrowth
pattern (pushingmargins),36 young age, and especially a rapid tumor
growth in gene mutation carriers.30,37-38 Moreover, as in other
studies,39-42 most of the invasive cancers in BRCA1mutation carriers
were high grade and estrogen receptor and progesterone receptor
negative, tumor characteristics which are, in general, also associated
with a more rapid tumor growth.
Our study is the first prospective study reporting mortality data
to our knowledge. Strikingly all five women developing an incurable
stage of disease (ie, distantmetastases) wereBRCA1/2mutation carri-
ers, including four women who died despite a favorable tumor stage
(T1cm,N0) in twoof them.Thisobservationunderscores theneed
for medical counselors to avoid guaranteeing that all breast cancer
deaths can be prevented by early detection of breast cancer as a result
of screening. Nevertheless, the low mortality up to 8.4 years from
diagnosis (median, 5.0 years) seems promising when compared to
previous studies,40,43,44with anoverall survival of 93%at6years.Until
now, breast cancer mortality reduction was simulated by predictive
models based on tumor stage at time of detection.29,32-34,45 The opti-
mal study design for demonstration of reduced mortality by inten-
sive surveillance is a randomized controlled trial. However, in the
absence of randomized studies currently and in the future (for ethical
reasons), we compared the overall survival of our patients with 26
historical cohorts of patients traced from the literature and from our
own institution in exploratory analyses (Appendix Fig A3, online
only).44,46,47 These 26 cohorts comprise totally 1,081 BRCA1/2
(BRCA1: n 751; BRCA2: n 330) mutation carriers (median, 42;
range, 14 to 170 patients per cohort) and show a median overall
survival of 74.5% (range, 50% to 95%). The 5-year cumulative overall
survival was higher in our prospectiveMRISC series of patients (93%;
95% CI, 79% to 98%) than in our institutional historical unselected
controls (170 BRCA1, 90 BRCA2)40,44 as well as in these 26 published
series. Furthermore,nodistantmetastasis anddeathswereobserved in
thehigh- andmoderate-risk groups of ourMRISC study.However, in
view of the absence of randomization or correction for lead-time or
forpotential differences in treatmentbetween studies, definite conclu-
sions on survival effects of specific screening strategies cannot yet be
made. Furthermore, cross-study comparisons of our observational
results with those of historical controls from the literature have strong
limitations in view of (possible) differences in populations, study
periods, methodology, and breast cancer management.
In conclusion, the update of our study confirms that with a
longer follow-up period (5 years) the sensitivity of MRI is still
strongly superior to that of mammography. In addition, and most
strikingly, BRCA1-associated tumors behave completely differ-
ently fromBRCA2-associated tumors and those from the other risk
groups in view of the younger age at diagnosis, lower mammo-
graphic sensitivity, the high proportion of interval cancers, the low
proportion of DCIS, and unfavorable tumor size at diagnosis. A
modification of the screening schedule for BRCA1mutation carri-
ers (eg, biannual MRI) or application of specific treatment regi-
mens48,49 or preventive measures5-8 (in view of two deaths in
women with very small tumors) may therefore be necessary in
order to further improve results on survival, which seempromising
with the current screening schedule.
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